Clinical Trials Browser

Active not recruiting × Thyroid cancer, Hurthle cell × Sorafenib × Clear all

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Phase 2 Active not recruiting

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell